Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21457575 | 1.00 | HSD11B1 (0.48) | HSD11B1BCHELY96METAP2KMT2A | |
| SCHEMBL10383610 | 0.84 | KDM4E (0.40) | KMT2AMEN1KDM4EENPP2 | |
| SCHEMBL9015162 | 0.83 | ENPP2 (0.36) | HSD11B1KDM4EENPP2 | |
| SCHEMBL26709208 | 0.79 | MEN1 (0.33) | HSD11B1KMT2AMEN1NPC1HSP90AA1 | |
| SCHEMBL11042660 | 0.78 | HSD11B1 (0.53) | HSD11B1BCHELY96KMT2AMEN1 | |
| SCHEMBL335510 | 0.78 | HSD11B1 (0.53) | HSD11B1BCHELY96KMT2AMEN1 | |
| SCHEMBL1751871 | 0.78 | HSD11B1 (0.62) | HSD11B1BCHELY96METAP2KMT2A | |
| SCHEMBL31613215 | 0.78 | HSD11B1 (0.62) | HSD11B1BCHELY96METAP2KMT2A | |
| SCHEMBL297691 | 0.78 | HSD11B1 (0.62) | HSD11B1BCHELY96METAP2KMT2A | |
| SCHEMBL8900317 | 0.78 | HSD11B1 (0.62) | HSD11B1BCHELY96METAP2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111606824-B | Beta-amino nitrile compound and preparation method thereof | 东北师范大学 | 2023-03-14 | — | — | CN | claimed |
| CN-111606824-A | Beta-amino nitrile compound and preparation method thereof | 东北师范大学 | 2020-09-01 | — | — | CN | claimed |
| CN-118084727-A | Method for preparing nitrile by catalyzing electron-deficient alkene or alkyne through heterogeneous metal manganese catalyst | 中国科学院大连化学物理研究所 | 2024-05-28 | — | — | CN | disclosed |
| CN-111606824-B | Beta-amino nitrile compound and preparation method thereof | 东北师范大学 | 2023-03-14 | — | — | CN | disclosed |
| EP-3553097-B1 | COPOLYMER AND OPTICAL FILM USING SAME | TOSOH CORP (JP) | 2022-05-04 | — | — | EP | disclosed |
| US-11225540-B2 | Copolymer and optical film using same | TOSOH CORPORATION (JP) | 2022-01-18 | — | — | US | disclosed |
| CN-110248971-B | Copolymer and optical film using the same | 东曹株式会社 | 2021-11-02 | — | — | CN | disclosed |
| CN-111606824-A | Beta-amino nitrile compound and preparation method thereof | 东北师范大学 | 2020-09-01 | — | — | CN | disclosed |
| US-20200095358-A1 | COPOLYMER AND OPTICAL FILM USING SAME | TOSOH CORPORATION (JP) | 2020-03-26 | — | — | US | disclosed |
| EP-3553097-A1 | COPOLYMER AND OPTICAL FILM USING SAME | Tosoh Corporation (JP) | 2019-10-16 | — | — | EP | disclosed |
| CN-110248971-A | Copolymer and the optical film for using the copolymer | 东曹株式会社 | 2019-09-17 | — | — | CN | disclosed |
| EP-2078029-B1 | ENANTIOMERICALLY PURE PHOSPHOINDOLE AS HIV INHIBITOR | IDENIX PHARMACEUTICALS INC (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8486991-B2 | Enantiomerically pure phosphoindoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110257129-A1 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS, INC. | 2011-10-20 | — | — | US | disclosed |
| US-7960428-B2 | (2-carbamoyl-5-chloro-1H-indol-3-yl)-[3-((E)-2-cyano-vinyl)-5-methyl-phenyl]-(S)-phosphinic acid methyl ester; Flaviviruses; bioavailability; pharmacokinetics | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| EP-2078029-A2 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX Pharmaceuticals, Inc. (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20080213217-A1 | Enantiomerically pure phosphoindoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| WO-2008042240-A9 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS INC (US) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008042240-A2 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257129-A1 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | DUSP3, PNP, PPP5C | HSD11B1 1670/4885BCHE 1844/4885LY96 3266/4885 |
| US-20080213217-A1 | Enantiomerically pure phosphoindoles as HIV inhibitors | DUSP3, PNP, PPP5C | HSD11B1 1670/4885BCHE 1844/4885LY96 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.